TRDA
Entrada Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
7.57
▼ 0.03 (0.39%)
MARKET · —
Price
Open
7.78
Prev close
7.60
Day high
7.74
Day low
7.44
Volume
138.40K
Market cap
$294.75M
P/E (TTM)
—
52W range
5.02 – 16.45
Trailing performance
Returnvs SPY
1W
+1.47%
+2.8%
1M
+25.12%
+21.4%
3M
+19.97%
+16.9%
6M
-32.95%
-44.0%
YTD
-26.36%
-38.7%
1Y
+42.56%
+22.6%
3Y
-51.84%
-126.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$294.75M
Enterprise value$98.49M
Revenue (TTM)$4.69M
Gross profit$-134.36M
EBITDA$-170.86M
Net income$-165.78M
EPS (TTM)$-3.96
Free cash flow$-77.67M
Total cash$223.00M
Total debt$48.54M
Book value / share$7.52
Shares outstanding38.94M
Float24.00M
Short % of float8.54%
Dividend yield—
Beta (5Y)-0.26
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.41
PEG ratio—
Price / sales—
Price / book1.01
EV / revenue21.02
EV / EBITDA-0.58
Gross margin0.00%
Operating margin-5007.02%
Profit margin0.00%
Return on equity-54.10%
Return on assets-29.20%
Debt / equity20.80
Current ratio10.89
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $25.42M | $210.78M | $129.01M | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$143.75M | $65.63M | -$6.68M | -$94.62M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$143.75M | $65.63M | -$6.68M | -$94.62M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.04 | -1.01 | +3.2% |
| Mar 2026 | -1.02 | -0.95 | +6.9% |
| Dec 2025 | -1.16 | -0.94 | +18.7% |
| Sep 2025 | -0.97 | -1.06 | -9.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.98 | 7 | $5.26M | +225.8% |
| Next quarter | -0.87 | 7 | $9.83M | +656.6% |
| Current year | -3.66 | 6 | $19.05M | -25.1% |
| Next year | -3.14 | 7 | $20.00M | +5.0% |
Analyst targets & ownership
Mean target$19.00
High target$25.00
Low target$11.00
Implied upside150.99%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 7
Hold1
Sell / Strong sell0 / 0
Held by insiders12.27%
Held by institutions83.36%
Institutions holding181
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-218.30K
Net selling
Buy transactions
6
315.60K shares
Sell transactions
10
533.90K shares
Net transactions
+16
Buys less sells
Sell : buy shares
1.7 : 1
Mixed
Insider-held shares
4.43M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | PARMAR KUSH M Director |
SELL | 155.25K | $1.08M | Indirect |
| Aug 7, 26 | 5AM VENTURES V, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 62.81K | $431.83K | Indirect |
| Jul 31, 26 | PARMAR KUSH M Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 116.47K | $807.03K | Indirect |
| Jul 31, 26 | 5AM VENTURES V, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 116.47K | $807.03K | Indirect |
| May 20, 26 | ZEIHER BERNHARDT G Director |
BUY | 5.00K | $29.32K | Indirect |
| May 4, 26 | DOWDEN NATHAN J President |
CONVERSION | 15.00K | $26.10K | Direct |
| May 4, 26 | DOWDEN NATHAN J President |
SELL | 15.00K | $229.95K | Direct |
| May 4, 26 | SETHURAMAN NATARAJAN Officer |
SELL | 25.91K | $398.81K | Direct |
| Apr 1, 26 | WENTWORTH KORY JAMES Chief Financial Officer |
SELL | 2.50K | $32.38K | Direct |
| Mar 10, 26 | WENTWORTH KORY JAMES Chief Financial Officer |
SELL | 16.48K | $214.38K | Direct |
| Mar 10, 26 | DOWDEN NATHAN J President |
SELL | 15.01K | $195.77K | Direct |
| Mar 4, 26 | WENTWORTH KORY JAMES Chief Financial Officer |
SELL | 7.99K | $97.89K | Direct |
| Feb 27, 26 | DOSHI DIPAL Chief Executive Officer |
STOCK | 139.40K | $0 | Direct |
| Feb 27, 26 | WENTWORTH KORY JAMES Chief Financial Officer |
STOCK | 44.60K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
5AM VENTURES V, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
DOSHI DIPAL |
Chief Executive Officer | 526.01K | Stock Award(Grant) |
DOWDEN NATHAN J |
President | 198.59K | Conversion of Exercise of derivative security |
MPM BIOVENTURES III, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
PARMAR KUSH M |
Director | — | Sale |
SETHURAMAN NATARAJAN |
Officer | 216.32K | Sale |
WENTWORTH KORY JAMES |
Chief Financial Officer | 119.01K | Sale |
ZEIHER BERNHARDT G |
Director | — | Purchase |
Moving averages & technicals
SMA 10
7.41
+2.15% from price
SMA 20
7.07
+7.05% from price
SMA 50
7.00
+8.13% from price
SMA 100
8.66
-12.56% from price
SMA 200
9.69
-21.90% from price
EMA 12
7.35
+2.97% from price
EMA 26
7.16
+5.72% from price
EMA 50
7.33
+3.29% from price
RSI (14)
57.6
Neutral
MACD (12,26,9)
0.19
Hist 0.08
ATR (14)
0.46
6.10% of price
Realised vol 30D
67.9%
Annualised
Bollinger upper
8.06
20, 2σ
Bollinger lower
6.08
20, 2σ
50 / 200 cross
Death
7.00 vs 9.69
Trend bias
Below 200
-21.90%
Risk profile
Beta vs SPY
1.46
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
67.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-64.8%
Peak to trough
Max drawdown 5Y
-85.7%
Peak to trough
ATR 14
0.46
6.10% of price
Beta (reported)
-0.26
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.74
Call-heavy session
Put / call open interest
0.17
Positioning, not flow
Max pain
7.50
-0.9% from spot
ATM implied vol
116.4%
Nearest strike to spot
Skew (10% OTM)
+191.0%
Puts bid over calls
Call volume
23
Contracts, this expiry
Put volume
17
Contracts, this expiry
Heaviest call OI
7.50
189 contracts
Heaviest put OI
10.00
41 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 17d ago
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · 17d ago
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing
MT Newswires · 19d ago
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 19d ago
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 23d ago
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
GlobeNewswire · 81d ago
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 82d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.